Development of Cordycepin Formulations for Preclinical and Clinical Studies
- 307 Downloads
There is extensive literature on in vivo studies with cordycepin, but these studies were generally conducted without validation of the various formulations, especially in terms of the solubility of cordycepin in the dosing vehicles used. Cordycepin is a promising drug candidate in multiple therapeutic areas, and there is a growing interest in studies aimed at assessing the pharmacological activity of this compound in relevant animal disease models. It is likely that many reported in vivo studies used formulations in which cordycepin was incompletely soluble. This can potentially confound the interpretation of pharmacokinetics and efficacy results. Furthermore, the presence of particles in intravenously administered suspension can cause adverse effects and should be avoided. Here, we present the results from our development of simple and readily applicable formulations of cordycepin based on quantitative solubility assessment. Homogeneous solutions of cordycepin were prepared in phosphate-buffered saline (PBS) at different pH levels, suitable as formulations for both intravenously and oral administration. For the purpose of high-dose oral administration, we also developed propylene glycol (PPG)-based vehicles in which cordycepin is completely soluble. The stability of the newly developed formulations was also assessed, as well as the feasibility of their sterilisation by filtration. Additionally, an HPLC-UV method for the determination of cordycepin in the formulations, which may also be useful for other purposes, was developed and validated. Our study could provide useful information for improvement of future preclinical and clinical studies involving cordycepin.
KEY WORDScordycepin formulation solubility stability HPLC-UV
The research was funded by Arthritis Research UK grant 20795 awarded to CHdM.
- 4.Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to cordycepin. 3. Biotech. 2014;4(1):1–12.Google Scholar
- 5.Lee J, Hong S, Yun J, Myoung H, Kim M. Anti-cancer effects of cordycepin on oral squamous cell carcinoma proliferation and apoptosis in vitro. J Cancer Ther. 2011;2(2):224–234.Google Scholar
- 7.Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. 3. Biotech. 2012;2(1):1–15.Google Scholar
- 9.Cho MA, Lee DS, Kim MJ, Sung JM, Ham SS. Antimutagenicity and cytotoxicity of cordycepin isolated from Cordyceps militaris. Food Sci Biotechnol. 2003;12(5):472–5.Google Scholar
- 15.Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK, et al. Cordycepin inhibits IL-1 beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology. 2009;48(1):45–8.Google Scholar
- 29.Dou C, Cao Z, Ding N, Hou TY, Luo F, Kang F, et al. Cordycepin prevents bone loss through inhibiting osteoclastogenesis by scavenging ROS generation. Forum Nutr. 2016;8(4):231.Google Scholar
- 46.U.S. Department of Health and Human Servies, Food and Drug Administration, Guidance for Industry, Analytical Procedures and Methods Validation for Drugs and Biologics. 2015.Google Scholar
- 47.U.S. Department of Health and Human Servies, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation. 2001.Google Scholar
- 51.World Health Organization. Guide to good storage practices for pharmaceuticals. WHO Technical Report Series. 2003;908(Annex 9).Google Scholar